Abeona Therapeutics Inc Asset Resilience Ratio
Abeona Therapeutics Inc asset resilience ratio. Abeona Therapeutics Inc (ABEO) has an Asset Resilience Ratio of 50.47% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Abeona Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abeona Therapeutics Inc (2000–2025)
Asset resilience ratio of Abeona Therapeutics Inc from 2000 to 2025. This chart shows how Abeona Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of Abeona Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abeona Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Abeona Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $90.60 Million | 50.47% |
| Total Liquid Assets | $90.60 Million | 50.47% |
Asset Resilience Insights
- Very High Liquidity: Abeona Therapeutics Inc maintains exceptional liquid asset reserves at 50.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abeona Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Abeona Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Abeona Therapeutics Inc Asset Resilience Ratio by Year (2000–2025)
Abeona Therapeutics Inc asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Abeona Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.45% | $112.97 Million | $219.57 Million | -16.82pp |
| 2024-12-31 | 68.27% | $74.36 Million | $108.93 Million | +9.28pp |
| 2023-12-31 | 58.99% | $37.75 Million | $64.00 Million | -0.08pp |
| 2022-12-31 | 59.07% | $37.93 Million | $64.21 Million | +43.89pp |
| 2021-12-31 | 15.19% | $12.09 Million | $79.59 Million | -39.34pp |
| 2020-12-31 | 54.52% | $82.44 Million | $151.20 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $223.38 Million | -- |
| 2018-12-31 | 37.97% | $66.22 Million | $174.40 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $178.77 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $111.06 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $80.06 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $16.58 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.73 Million | -- |
| 2011-12-31 | 8.72% | $330.00K | $3.79 Million | -65.19pp |
| 2007-12-31 | 73.91% | $6.76 Million | $9.15 Million | +24.19pp |
| 2006-12-31 | 49.72% | $3.19 Million | $6.43 Million | +47.99pp |
| 2005-12-31 | 1.73% | $125.00K | $7.21 Million | -2.65pp |
| 2004-12-31 | 4.38% | $486.00K | $11.09 Million | -11.37pp |
| 2003-12-31 | 15.75% | $1.86 Million | $11.81 Million | -27.01pp |
| 2002-12-31 | 42.76% | $8.33 Million | $19.49 Million | -7.07pp |
| 2001-12-31 | 49.83% | $12.70 Million | $25.49 Million | -7.15pp |
| 2000-12-31 | 56.98% | $17.39 Million | $30.53 Million | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more